DANAHER CORP /DE/ (DHR): what the price requires
At today's price, DANAHER CORP /DE/ (DHR) is priced for today's economics sustained for ~5.6 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-13 · Source: https://boothcheck.com/report/DHR
Headline
| Field | Value |
|---|---|
| Ticker | DHR |
| Company | DANAHER CORP /DE/ |
| Current price | $200.15/sh |
| Composition | Recurring 82% / Nonrecurring 18% |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 22.1% |
| Operating margin today | 19.1% |
| Margin expansion implied | +3.0pp |
| Must persist for | 5.6y |
| Multiple paid | 35x operating income |
The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.
Solve inputs: computed at a 8.5% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~1.9 years.
How unusual the bet is: elevated
| Reference | Value |
|---|---|
| vs own history | +0.95σ |
| cohort percentile (of 177 peers) | 64 |
| sustained it ~5.6 years at this level | 28% |
| implied end-window share | 0% |
Valuation X-Ray
Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 4.15x | 5 | expensive |
| Earnings | 3.77x | 5 | expensive |
| Relative | 2.30x | 3 | expensive |
| Growth | 1.32x | 3 | expensive |
Families that call it expensive: Asset, Earnings, Relative
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.2%); the inversion above states its own rate.
Per-Model Detail (n=16)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $151.09 | 1.32x | yes | FCF base $5.3B, growth 4% (input: historical growth), terminal g 4.0%, WACC 8.2%, 5yr projection |
| DCF Exit Multiple | Growth | $184.14 | 1.09x | yes | Exit EV/EBITDA: 27.3x / 29.3x / 31.3x (bear / base = today's held flat / bull), 5yr |
| Relative Valuation | Relative | $118.26 | 1.69x | yes | P/E 24.18x (blended: sector 18x + trailing (TTM) 39x), scenarios: 20.4x / 24.2x / 28.0x (bear / base = sector held flat / bull), EV/EBITDA 17.19x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $56.08 | 3.57x | yes | BV/sh $74.45, ROE (TTM) 7.0%, ke 9.3% |
| Two-Stage Excess Return | Asset | $48.25 | 4.15x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $149.86 | 1.34x | yes | Rev $24.8B, growth 4% (input: historical growth; tapered), Terminal P/S: 4.8x / 5.7x / 6.6x (bear / base = today's held flat / bull, cap 8x) |
| Growth-Adjusted P/E | Relative | — | — | no | — |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $64.08 | 3.12x | yes | Normalized EBIT (5y avg op income, one-time charges added back) $6.32B × (1−17%) / WACC 8.2% → EPV (no growth) |
| Residual Income | Asset | $47.13 | 4.25x | yes | BV $74.45 + 5yr PV of (ROE (TTM) 7.0% − Kₑ 9.3%) × BV; BV grows 4.5%/yr |
| Graham Number | Asset | $93.15 | 2.15x | yes | √(22.5 × EPS $5.18 × BVPS $74.45) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $65.88 | 3.04x | yes | EBITDA $5.52B × sector EV/EBITDA 12.0x |
| FCF Yield | Earnings | $53.14 | 3.77x | yes | FCF $5291.0M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $48.66 | 4.11x | yes | SBC-adj FCF $5.00B (FCF $5.29B − SBC $0.29B) capitalized at Kₑ |
| Ben Graham Formula | Earnings | $34.78 | 5.75x | yes | EPS $5.18 × (8.5 + 2×-0.2%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | $14.10 | 14.19x | yes | BV $74.45 × (ROIC 1.5% / WACC 8.2%) |
| P/Sales Sector | Relative | $87.10 | 2.30x | yes | Revenue $24.78B × sector P/S 2.5x |
| PEG Fair Value | Relative | — | — | no | — |
| Earnings Yield | Earnings | $56.00 | 3.57x | yes | EPS $5.18 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $19.4b |
| Net debt / NOPAT (after-tax) | 5.14x |
| Net debt / operating income (pre-tax) | 4.28x |
| Interest coverage | 16.6x |
| Share count CAGR (buyback) | -3.9% |
| Burning cash | no |
Bullet Takeaways
- Danaher is a life-sciences and diagnostics conglomerate built on recurring revenue: its bioprocessing tools, diagnostics, and consumables sell over and over to drugmakers and labs, and the prized bioprocessing business just posted its first order growth in nearly two years, up more than 30%.
- The biggest risk is China and policy: a large share of growth comes from high-growth markets, and Chinese volume-based procurement reforms plus a soft respiratory season are pressuring the diagnostics franchise, including Cepheid.
- Watch the bioprocessing recovery and guidance: management raised full-year 2026 adjusted EPS guidance to $8.35 to $8.55 and expects core revenue growth to accelerate to a mid-single-digit pace by year-end as the headwinds fade.
Bull Case
The market prices Danaher like a premium compounder, and the bull case is that the fundamentals are quietly inflecting back to justify it. The single most important development is the bioprocessing recovery: equipment orders grew more than 30% year over year in the most recent quarter, the first positive growth in almost two years. Bioprocessing, the tools and consumables that drugmakers use to manufacture biologic medicines, is Danaher's crown jewel, and orders lead revenue by several quarters. After a long destocking hangover from the pandemic-era overbuild, orders turning positive is the leading signal that the most valuable part of the company is coming back.
The quality of the revenue is what earns the premium. A large and growing share of Danaher's sales is recurring: consumables, reagents, and service that customers buy continuously once they have standardized on Danaher's instruments. The biotechnology segment grew core revenue 7% with double-digit bioprocessing growth in China and strong consumables demand globally, and Cepheid's core non-respiratory diagnostic menu grew mid-teens, led by 20% growth in sexual-health and hospital-acquired-infection testing. That recurring base, spread across academic, clinical, and commercial drug-development customers, is the kind of sticky, repeat revenue that holds up across cycles, which is precisely what the valuation methods cannot capture when only one of them reaches the price.
The reason every backward-looking valuation lens reads Danaher as expensive is partly an accounting artifact, and that is itself part of the bull case. Danaher grows by acquiring businesses and running them through the Danaher Business System, and those acquisitions generate large amortization of acquired intangibles that depresses GAAP earnings. The 10-K explains that "business acquisitions typically result in the recognition of goodwill, developed technology" and other intangibles. Free cash flow, which strips out that non-cash amortization, is far healthier than GAAP earnings suggest, exceeding $5 billion. Management raised full-year 2026 adjusted earnings guidance and expects core growth to accelerate to a mid-single-digit exit rate by year-end. The bull case is a high-quality, recurring-revenue compounder at the start of a bioprocessing upturn, where the gap between depressed GAAP optics and strong underlying cash flow is the opportunity.
Bear Case
The external variable with the most leverage on Danaher's thesis is China, and it is moving against the company. A meaningful slice of growth comes from high-growth markets, and China is implementing volume-based procurement reforms that systematically drive down the prices paid for diagnostics and medical products. The 10-K is candid that the Chinese government "plays a significant role in regulating industry development by imposing sector-specific policies" and controls economic treatment of particular industries. When a government sets out to compress the prices of the exact products Danaher sells, it pressures both volume and margin in a market the company cannot easily exit, and the diagnostics franchise, including Cepheid, is feeling it now alongside a soft respiratory testing season.
The valuation amplifies any disappointment because the price assumes a lot. Of the standard methods, only the growth-based one reaches the price; the asset, earnings-power, and peer-multiple lenses all read Danaher as richly valued, several at multiples of where the price sits. The inversion implies operating growth around 24% a year sustained for years, a pace only about a third of comparable fast-growers have managed. The bull's answer is that GAAP earnings understate the business, which is true, but even on cash flow the multiple is full, and the recovery in bioprocessing, while real in orders, has not yet shown up in revenue, which management noted remained roughly flat. The price is paying for the recovery to complete and accelerate; if it stalls, the premium has a long way to fall toward the conservative methods.
The structural feature underneath is the acquisition treadmill. Danaher's growth model depends on continually buying businesses and improving them, which works brilliantly when the deals are good and the integration delivers, but carries real risks: overpaying in a competitive market for assets, integration missteps, and a balance sheet that carries about $19 billion of net debt to fund the deals. The recurring large amortization charges are the financial footprint of that strategy, and while interest coverage is comfortable at over eighteen times, the model requires a steady supply of attractively priced targets. The price already credits the compounding continuing indefinitely. The bear is not that Danaher is a weak business; it is one of the best-run companies in its sector. The bear is that a premium priced for 20%-plus compounding leaves no room for the China headwind to deepen, the bioprocessing recovery to disappoint, or the next acquisition to be a stretch, and any of those would reprice a stock the static methods already say is expensive.
Valuation
Danaher's price asks the business to keep compounding at a rate few companies sustain. At roughly 31 times operating income, the inversion implies company-wide operating growth around 24% a year, a pace the framework flags as elevated and that only about a third of comparable fast-growers held even five years. One important caveat: the GAAP operating income the multiple is measured against is depressed by amortization of acquired intangibles, so the headline multiple overstates how expensive the cash-generating business really is. Free cash flow exceeds $5 billion, well above GAAP earnings, which is why a single multiple read on reported profit is the wrong lens for an acquisition-driven compounder.
The methods we use to triangulate are lopsided, and the pattern names the bet. Every backward-looking lens, asset value, normalized earnings power, peer multiples, lands well below the price, several at a fraction of it, dragged down by the GAAP earnings and the low reported return on equity that the intangible amortization produces. Only the growth-based discounted cash-flow method reaches the price, and it does so by crediting durable forward compounding. Read honestly, that is a moat-and-durability premium: the static frames structurally cannot price a recurring-revenue compounder mid-recovery, so the market pays forward for the bioprocessing upturn and the Danaher Business System to keep delivering. The spread between the conservative methods and the price is the entire premium, and it rests on the recovery and the acquisition engine continuing.
Solvency is sound and supports the model rather than constraining it. Net debt of about $19 billion is roughly four times operating income, manageable for a stable, cash-generative business, and interest coverage runs above eighteen times. The cash flow funds both the acquisition program and a modest, steady reduction in the share count. The downside is bounded by the recurring-revenue base and the quality of the franchises, not by zero, and the balance sheet gives Danaher the flexibility to keep acquiring through the cycle. The buyer at this price is paying a durability premium for a best-in-class compounder, underwriting the bioprocessing recovery, continued recurring-revenue growth, and a steady supply of value-accretive deals, with the China policy headwind and the full multiple as the main risks to the bet.
Catalysts
Danaher's first quarter of 2026 carried one decisive positive and a couple of known drags. The decisive positive was bioprocessing: equipment orders grew more than 30% year over year, the first positive growth in nearly two years, even though equipment revenue stayed roughly flat as expected. Because orders lead revenue, that inflection is the catalyst the bull case has been waiting for, signaling that the long pandemic-era destocking in biologic-drug manufacturing tools has run its course. Biotechnology core revenue grew 7%, with double-digit bioprocessing growth in China and strong global consumables demand.
The offsetting pressures were in diagnostics. A lighter-than-normal respiratory season weighed on Cepheid's testing volumes, and China's volume-based procurement reforms continued to pressure diagnostics pricing. Cepheid's underlying menu was healthier than the headline, with core non-respiratory tests up mid-teens, led by 20% growth in sexual-health and hospital-acquired-infection assays. The mixed quarter, strength in bioprocessing offset by diagnostics headwinds, is why management framed the year as a back-half acceleration story.
On guidance, Danaher raised full-year 2026 adjusted diluted EPS guidance to a range of $8.35 to $8.55 while keeping its 3% to 6% core revenue growth outlook, and it expects core growth to accelerate to a mid-single-digit exit rate by year-end as the respiratory and China headwinds moderate. Those are company-defined adjusted figures that exclude acquisition-related amortization and other items. The catalysts to watch are whether bioprocessing orders translate into revenue growth over the coming quarters, whether the China diagnostics pressure stabilizes, and the pace of the core-growth acceleration management has promised. The bioprocessing revenue conversion is the single data point that most directly tests whether the premium valuation is earned.
Peer Cohorts (Per Segment, With Filing Citations)
Biotechnology / Life Sciences / Diagnostics (reported)
- TMO (THERMO FISHER SCIENTIFIC INC.)
- (no filing in the citation store)
- A (AGILENT TECHNOLOGIES, INC.)
- (no filing in the citation store)
- MTD (Mettler-Toledo International Inc.)
- (no filing in the citation store)
- WAT (Waters Corporation)
- (no filing in the citation store)
- RVTY (REVVITY, INC)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
Q1 2026 results, April 2026 · Q1 2026 guidance · Q1 2026 earnings call